Navigation Links
Absorption Pharmaceuticals' CEO Jeff Abraham Discusses Promescent on KFI
Date:8/8/2014

LOS ANGELES, Aug. 8, 2014 /PRNewswire/ -- Jeff Abraham, CEO for Absorption Pharmaceuticals, was featured on KFI AM 640 on Wednesday, August 6, 2014, where he discussed Promescent, the first FDA-approved treatment for premature ejaculation (PE). Abraham answered callers' question regarding PE and explained how Promescent would safely and effectively improve their sex lives. 

According to statistics, more than 30 percent of men are currently struggling with premature ejaculation, much larger than the number of men who suffer from erectile dysfunction, a $10B worldwide market.  In his segment on KFI, Jeff Abraham explained how Promescent is able to provide men with superior ejaculatory control, with an extremely low side effect profile, common concerns surrounding other treatments for the disorder.

"Promescent may seem like a miracle, but it is actually just great science," says Abraham.  "Using a precise ratio of active ingredients, Promescent is able to absorb through the skin's outermost layer to the nerves below that control ejaculation.  This means men are not deprived of sensation and neither are their partners."

Listen to the full KFI interview with Absorption Pharmaceuticals CEO Jeff Abraham here:

http://www.kfiam640.com/media/podcast-john-and-ken-on-demand-JohnandKen/jane-wells-cnbc-6pm-86-25128155/

Promescent is now considered the leading PE solution in the U.S. with solid support from the medical community. Leaders in sexual medicine along with more than 1,000 urologists use Promescent as first-line therapy for premature ejaculation, replacing off-label anti-depressants and EMLA topical anesthetic.

"We're finding that an increasing portion of our business is from men who don't suffer from PE but simply want to last longer in bed," says Abraham.  "This helps men better satisfy their partners and gain sexual confidence."

Promescent is available on-line and over-the-counter at independent pharmacies across the nation.  It is safe, effective, and doctor recommended. 

For more information, please visit http://www.promescent.com/.

To set up an interview and/or media inquiries, call Tyler Barnett at 323.937.1951.


'/>"/>
SOURCE Absorption Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Absorption Systems announces novel test platform for interactions with the BCRP transporter
2. Absorption Systems Registers with FDA as a Generic Drug Facility under GDUFA
3. Absorption Systems Partners with Synerzys to Promote Biopharmaceutics Classification System (BCS) Testing of Drugs
4. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
5. Vatsala Naageshwaran of Absorption Systems to Present at Disso 2013 International Conference in Mumbai, India on May 3rd
6. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
7. Absorption Systems Scientists Publish Peer-reviewed Paper on a Key Drug Transporter
8. Absorption Pharmaceuticals Expands Sales and Service Team to Answer Physicians Growing Demand for Promescent
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... Report Highlights: The report ... the investment opportunities Market forecasts till 2025, using estimated ... across the business segments, Regions and Countries Key developments ...
(Date:1/23/2017)... , Jan. 23, 2017  Using Astute ... at high risk for acute kidney injury (AKI) ... by globally-recognized care guidelines significantly improved ... severe AKI more than 33 percent, according to ... the journal Intensive Care Medicine. ...
(Date:1/23/2017)... 23, 2017 Ahead of today,s trading session, ... they have fared at the close: Kite Pharma Inc. (NASDAQ: ... OVAS ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... relative laggards on Friday, January 20 th , 2017, down on ... reports on these stocks now at: ...
Breaking Medicine Technology:
(Date:1/23/2017)... ... January 23, 2017 , ... ... services for life science companies, has achieved ISO 17100:2015 certification following a ... ISO 17100 is the globally recognized standard that establishes guidance for critical ...
(Date:1/23/2017)... ... 2017 , ... The iaedp Foundation, recognized for its excellence ... treat the full spectrum of eating disorder problems, proudly announces the addition of ... the leading eating disorder treatments centers located throughout the U.S. As partners of ...
(Date:1/23/2017)... ... January 23, 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate ... about the benefits of making new water infrastructure a number one priority. “As we ... we expect water infrastructure to become a top priority of our new political change ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Crystallization in Process Chemistry by Applying Simple PAT Tools . , Crystallization ... isolate and purify the desired product. Chemists now spend more time developing ...
(Date:1/23/2017)... ... ... is a set of camera tools that allow video editors to integrate up to two ... Christina Austin - CEO of Pixel Film Studios. , With ProRandom, video editors can ... ProRandom works by using a virtual camera to create the illusion of a shaky camera. ...
Breaking Medicine News(10 mins):